These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
540 related articles for article (PubMed ID: 35690723)
1. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. Sacco S; Amin FM; Ashina M; Bendtsen L; Deligianni CI; Gil-Gouveia R; Katsarava Z; MaassenVanDenBrink A; Martelletti P; Mitsikostas DD; Ornello R; Reuter U; Sanchez-Del-Rio M; Sinclair AJ; Terwindt G; Uluduz D; Versijpt J; Lampl C J Headache Pain; 2022 Jun; 23(1):67. PubMed ID: 35690723 [TBL] [Abstract][Full Text] [Related]
2. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064 [TBL] [Abstract][Full Text] [Related]
3. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today? Nagaraj K; Vandenbussche N; Goadsby PJ Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149 [TBL] [Abstract][Full Text] [Related]
4. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Tepper SJ Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830 [TBL] [Abstract][Full Text] [Related]
5. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Charles AC; Digre KB; Goadsby PJ; Robbins MS; Hershey A; Headache; 2024 Apr; 64(4):333-341. PubMed ID: 38466028 [TBL] [Abstract][Full Text] [Related]
6. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine. Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581 [TBL] [Abstract][Full Text] [Related]
7. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor. Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society. Aleksovska K; Hershey AD; Deen M; Icco R; Lee MJ; Diener HC Cephalalgia; 2023 Oct; 43(10):3331024231206162. PubMed ID: 37879637 [TBL] [Abstract][Full Text] [Related]
9. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Tepper SJ Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405 [TBL] [Abstract][Full Text] [Related]
10. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants. Chiang CC; Schwedt TJ Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505 [TBL] [Abstract][Full Text] [Related]
11. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention. Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640 [TBL] [Abstract][Full Text] [Related]
13. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies. Nsaka M; Scheffler A; Wurthmann S; Schenk H; Kleinschnitz C; Glas M; Holle D Brain Behav; 2022 Jul; 12(7):e2662. PubMed ID: 35687795 [TBL] [Abstract][Full Text] [Related]
14. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class. Arca K; Reynolds J; Sands KA; Shiue HJ Ann Pharmacother; 2020 Aug; 54(8):795-803. PubMed ID: 32019317 [No Abstract] [Full Text] [Related]
15. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy. Raffaelli B; Reuter U Neurotherapeutics; 2018 Apr; 15(2):324-335. PubMed ID: 29616494 [TBL] [Abstract][Full Text] [Related]
16. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany. Hong JB; Lange KS; Fitzek M; Overeem LH; Triller P; Siebert A; Reuter U; Raffaelli B J Headache Pain; 2023 Oct; 24(1):144. PubMed ID: 37899428 [TBL] [Abstract][Full Text] [Related]
17. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials. Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047 [TBL] [Abstract][Full Text] [Related]
18. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Edvinsson L; Haanes KA; Warfvinge K; Krause DN Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490 [TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. Messina R; Huessler EM; Puledda F; Haghdoost F; Lebedeva ER; Diener HC Cephalalgia; 2023 Mar; 43(3):3331024231152169. PubMed ID: 36786548 [TBL] [Abstract][Full Text] [Related]
20. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. De Matteis E; Guglielmetti M; Ornello R; Spuntarelli V; Martelletti P; Sacco S Expert Rev Neurother; 2020 Jun; 20(6):627-641. PubMed ID: 32434430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]